for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Palatin Technologies, Inc.

PTN

Latest Trade

0.46USD

Change

-0.01(-1.25%)

Volume

389,575

Today's Range

0.45

 - 

0.47

52 Week Range

0.38

 - 

1.30

As of on the Nyse American LLC ∙ Minimum 15 minute delay

Pricing

Previous Close
0.46
Open
0.45
Volume
389,575
3M AVG Volume
25.76
Today's High
0.47
Today's Low
0.45
52 Week High
1.30
52 Week Low
0.38
Shares Out (MIL)
230.12
Market Cap (MIL)
106.41
Forward P/E
-4.03
Dividend (Yield %)
--

Next Event

Q4 2021 Palatin Technologies Inc Earnings Release

Latest Developments

More

Palatin Announces Positive End-Of-Phase 2 Meeting With FDA On Pl9643 For The Treatment Of Dry Eye Disease

Palatin Reports Q3 Loss Per Share Of $0.02

Palatin Technologies Reports Q2 Fiscal Year 2021 Financial Results And Recent Business Highlights

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Palatin Technologies, Inc.

Palatin Technologies, Inc. (Palatin) is a biopharmaceutical company. The Company is engaged in developing medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. The Company’s product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with unmet medical need and commercial potential. The melanocortin receptor (MCr) system is hormone driven, with effects on food intake, metabolism, sexual function, inflammation and immune system responses. There are five melanocortin receptors, MC1r through MC5r. The natriuretic peptide receptor (NPR) system regulates cardiovascular functions, and therapeutic agents modulating this system have potential to treat fibrotic diseases, cardiovascular diseases, including reducing cardiac hypertrophy and fibrosis, heart failure, acute asthma, pulmonary diseases and hypertension.

Industry

Biotechnology & Drugs

Contact Info

4B Cedar Brook Drive

CRANBURY, NJ

08512

United States

+1.609.4952200

https://www.palatin.com/

Executive Leadership

John K. A. Prendergast

Independent Chairman of the Board

Carl Spana

President, Chief Executive Officer, Director

Stephen T. Wills

Chief Financial Officer, Chief Operating Officer, Executive Vice President, Treasurer, Secretary

Robert K. deVeer

Independent Director

Alan William Dunton

Independent Director

Key Stats

1.33 mean rating - 3 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.1K

2019

0.1K

2020

0.0K

2021(E)

0.0K
EPS (USD)

2018

0.120

2019

0.160

2020

-0.100

2021(E)

-0.113
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
1.69
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-34.23
Return on Equity (TTM)
-31.55

Latest News

Latest News

BRIEF-Palatin Technologies Announces Reinitiation Of Enrollment Of Phase 2 Study With Pl9643 For Treatment Of Dry Eye Disease

* PALATIN TECHNOLOGIES, INC. ANNOUNCES REINITIATION OF ENROLLMENT OF PHASE 2 STUDY WITH PL9643 FOR THE TREATMENT OF DRY EYE DISEASE

BRIEF-Palatin Technologies To Develop Pl8177 As A Potential Treatment For Covid-19

* PALATIN TECHNOLOGIES TO DEVELOP PL8177 AS A POTENTIAL TREATMENT FOR COVID-19 AND ASSOCIATED LUNG COMPLICATIONS

BRIEF-Palatin Technologies Reports Q3 Loss Per Share $0.02

* PALATIN TECHNOLOGIES, INC. REPORTS THIRD QUARTER FISCAL YEAR 2020 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS

BRIEF-Palatin Technologies Inc - Cash And Cash Equivalents Of $88.9 Million As Of March 31, 2020

* PALATIN TECHNOLOGIES INC - CASH AND CASH EQUIVALENTS OF $88.9 MILLION AS OF MARCH 31, 2020

BRIEF-Palatin Tech Announces First Patient Enrolled In Dry Eye Disease Phase 2 Clinical Trial With Pl9643

* PALATIN TECHNOLOGIES, INC. ANNOUNCES FIRST PATIENT ENROLLED IN DRY EYE DISEASE PHASE 2 CLINICAL TRIAL WITH PL9643

BRIEF-Palatin Technologies Q2 Loss Per Share $0.02

* PALATIN TECHNOLOGIES, INC. REPORTS SECOND QUARTER FISCAL YEAR 2020 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS

FDA approves drug for loss of sexual desire in women

The U.S. drug regulator on Friday approved Palatin Technologies and Amag Pharmaceuticals' drug to restore sexual desire in premenopausal women, the latest attempt to come up with a therapy that some have dubbed as "female Viagra".

FDA approves drug for loss of female sexual desire

The U.S. Food and Drug Administration on Friday approved Palatin Technologies Inc and Amag Pharmaceuticals Inc's drug to restore sexual desire in premenopausal women, Amag said.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up